blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3172202

EP3172202 - HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.12.2020
Database last updated on 28.06.2024
FormerThe patent has been granted
Status updated on  27.12.2019
FormerGrant of patent is intended
Status updated on  27.08.2019
FormerExamination is in progress
Status updated on  13.04.2018
FormerRequest for examination was made
Status updated on  28.04.2017
FormerThe international publication has been made
Status updated on  02.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2017/22]
Inventor(s)01 / BRENNEMAN, Jehrod Burnett
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
02 / GINN, John David
27 Bayberry Lane
New Milford, CT 06776 / US
03 / SARKO, Christopher Ronald
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
04 / WESTBROOK, John
1081 Racebrook Road
Woodbridge, CT 06525 / US
05 / ZHANG, Zhonghua
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
06 / YU, Maolin
48 Ledgewood Drive
Brookfield, CT 06804 / US
07 / HOPKINS, Tamara Denise
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
08 / LOWE, Michael D.
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
 [2020/05]
Former [2017/22]01 / BRENNEMAN, Jehrod Burnett
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
02 / GINN, John David
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
03 / SARKO, Christopher Ronald
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
04 / WESTBROOK, John
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
05 / ZHANG, Zhonghua
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
06 / YU, Maolin
48 Ledgewood Drive
Brookfield, CT 06804 / US
07 / HOPKINS, Tamara Denise
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
08 / LOWE, Michael D.
c/o VP
IP Legal
Boehringer Ingelheim USA Corp.
900 Ridgebury Rd., P.O. Box 368
Ridgefield, Connecticut 06877-0368 / US
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2017/22]
Application number, filing date15747311.721.07.2015
[2017/22]
WO2015US41245
Priority number, dateUS201462027376P22.07.2014         Original published format: US 201462027376 P
[2017/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016014463
Date:28.01.2016
Language:EN
[2016/04]
Type: A1 Application with search report 
No.:EP3172202
Date:31.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.01.2016 takes the place of the publication of the European patent application.
[2017/22]
Type: B1 Patent specification 
No.:EP3172202
Date:29.01.2020
Language:EN
[2020/05]
Search report(s)International search report - published on:EP28.01.2016
ClassificationIPC:C07D405/14, C07D417/14, A61K31/55, A61P13/12
[2017/22]
CPC:
C07D405/14 (EP,CN,KR,US); A61K31/444 (KR); A61K31/4725 (KR);
A61P1/16 (EP); A61P11/00 (EP); A61P13/08 (EP);
A61P13/10 (EP); A61P13/12 (EP); A61P15/00 (EP);
A61P15/10 (EP); A61P17/00 (EP); A61P21/00 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/16 (EP);
A61P25/28 (EP); A61P27/06 (EP); A61P29/00 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P9/00 (EP);
C07D417/14 (EP,CN,KR,US); C07D471/04 (CN) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/22]
Extension statesBA22.02.2017
ME22.02.2017
Validation statesMANot yet paid
TitleGerman:HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE[2017/22]
English:HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE[2017/22]
French:ACIDES CARBOXYLIQUES HÉTÉROCYCLIQUES EN TANT QU'ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE[2017/22]
Entry into regional phase22.02.2017National basic fee paid 
22.02.2017Designation fee(s) paid 
22.02.2017Examination fee paid 
Examination procedure02.12.2016Date on which the examining division has become responsible
22.02.2017Examination requested  [2017/22]
26.09.2017Amendment by applicant (claims and/or description)
16.04.2018Despatch of a communication from the examining division (Time limit: M04)
27.07.2018Reply to a communication from the examining division
05.09.2018Despatch of a communication from the examining division (Time limit: M04)
08.01.2019Reply to a communication from the examining division
07.05.2019Despatch of a communication from the examining division (Time limit: M02)
04.07.2019Reply to a communication from the examining division
28.08.2019Communication of intention to grant the patent
12.12.2019Fee for grant paid
12.12.2019Fee for publishing/printing paid
12.12.2019Receipt of the translation of the claim(s)
Opposition(s)30.10.2020No opposition filed within time limit [2021/01]
Fees paidRenewal fee
31.07.2017Renewal fee patent year 03
31.07.2018Renewal fee patent year 04
31.07.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL29.01.2020
CY29.01.2020
EE29.01.2020
FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
MC29.01.2020
MK29.01.2020
MT29.01.2020
RS29.01.2020
SI29.01.2020
SK29.01.2020
SM29.01.2020
NO29.04.2020
IS29.05.2020
LU21.07.2020
[2022/31]
Former [2022/28]CY29.01.2020
EE29.01.2020
FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
MC29.01.2020
MT29.01.2020
RS29.01.2020
SI29.01.2020
SK29.01.2020
SM29.01.2020
NO29.04.2020
IS29.05.2020
LU21.07.2020
Former [2021/20]EE29.01.2020
FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
MC29.01.2020
RS29.01.2020
SI29.01.2020
SK29.01.2020
SM29.01.2020
NO29.04.2020
IS29.05.2020
LU21.07.2020
Former [2021/13]EE29.01.2020
FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
MC29.01.2020
RS29.01.2020
SI29.01.2020
SK29.01.2020
SM29.01.2020
NO29.04.2020
IS29.05.2020
Former [2020/50]EE29.01.2020
FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
RS29.01.2020
SK29.01.2020
SM29.01.2020
NO29.04.2020
IS29.05.2020
Former [2020/48]FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
RS29.01.2020
SM29.01.2020
NO29.04.2020
IS29.05.2020
Former [2020/47]FI29.01.2020
HR29.01.2020
LT29.01.2020
LV29.01.2020
RS29.01.2020
NO29.04.2020
IS29.05.2020
Former [2020/40]FI29.01.2020
HR29.01.2020
LV29.01.2020
RS29.01.2020
NO29.04.2020
IS29.05.2020
Former [2020/37]FI29.01.2020
HR29.01.2020
LV29.01.2020
RS29.01.2020
NO29.04.2020
Former [2020/35]FI29.01.2020
NO29.04.2020
Cited inInternational search[IY]WO2012122340  (BOEHRINGER INGELHEIM INT [DE], et al) [I] 1-18 * Abstract; claims; examples e.g. compound no. 45 at page 28. * [Y] 1-18;
 [Y]WO2013025425  (BOEHRINGER INGELHEIM INT [DE], et al) [Y] 1-18* Abstract; claims; examples. *
by applicantWO2008138483
 WO2009043495
 WO2010081647
 WO2015095515
    - EVGENOV ET AL., NATURE REVIEWS, (2006), vol. 5, pages 755 - 768
    - Y. WANG-ROSENKE ET AL., CURR. MED. CHEM., (2008), vol. 15, pages 1396 - 1406
    - O. EVGENOV ET AL., NATURE REVIEWS, (2006), vol. 5, pages 755 - 768
    - J-P STASCH ET AL., BRIT J. PHARMACOL., (2002), vol. 136, pages 773 - 783
    - U. SCHINDLER ET AL., MOL. PHARMACOL., (2006), vol. 69, pages 1260 - 1268
    - K. HIRSCHBERG ET AL., CARDIOVASC. RES., (2010), vol. 87, no. 1, page S100
    - M. VAN EICKELS, BMC PHARMACOLOGY, (2007), vol. 7, no. 1, page 4
    - N. RIZZO ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., (2010), vol. 30, pages 758 - 765
    - D. ATOCHIN ET AL., STROKE, (2010), vol. 41, pages 1815 - 1819
    - C. WU, J. PHARMACOL. SCI., (2004), vol. 94, pages 252 - 260
    - V. LEISS ET AL., BMC PHARMACOLOGY, (2009), vol. 9, no. 1, page 40
    - S. GUR ET AL., CURR. PHARM. DES., (2010), vol. 16, pages 1619 - 1633
    - C. TEIXEIRA ET AL., J. PHARMACOL. & EXP. THER., (2007), vol. 322, pages 1093 - 1102
    - T. DUNKERN ET AL., EUR. J. PHARM., (2007), vol. 572, pages 12 - 22
    - S. VYAS-READ ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., (2007), vol. 293, pages 1212 - 1221
    - E. DREIEICHER ET AL., J. AM. SOC. NEPHROL., (2009), vol. 20, pages 1963 - 1974
    - A. KNORR ET AL., ARZNEIMITTEL-FORSCHUNG, (2008), vol. 58, pages 71 - 80
    - C. BEYER ET AL., ANN. RHEUM. DIS., (2012), vol. 71, pages 1019 - 1026
    - H. LAPP ET AL., CIRCULATION, (2009), vol. 119, pages 2781 - 2788
    - G. BOERRIGTER ET AL., HYPERTENSION, (2007), vol. 49, pages 1128 - 1133
    - F. DANIELA, CIRCULATION, (2009), vol. 120, no. 2, pages S852 - S853
    - J.-P. STASCH ET AL., J. CLIN. INVEST., (2006), vol. 116, pages 2552 - 2561
    - D. DAL SECCO, NITRIC OXIDE, (2006), vol. 15, pages 77 - 86
    - T. KRIEG ET AL., EUR. HEART J., (2009), vol. 30, pages 1607 - 6013
    - A.-M. PELLETIER ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., (2010), vol. 298, pages G896 - G907
    - C. PATIL ET AL., PHARM., (2004), vol. 72, pages 190 - 195
    - AGUIRRE-BANUELOS ET AL., EUR. J. PHARMACOL., (2000), vol. 395, pages 9 - 13
    - L. SAVEGNAGO ET AL., J. PHARMACY PHARMACOL., (2008), vol. 60, pages 1679 - 1686
    - T. ROMERO ET AL., EUR. J. PHARMACOL., (2009), vol. 613, pages 64 - 67
    - F. VAN DER STAAY ET AL., NEUROPHARMACOL., (2008), vol. 55, pages 908 - 918
    - K. DOMEK-LOPACINSKA ET AL., MOL. NEUROBIOL., (2010), vol. 41, pages 129 - 137
    - GHOFRANI ET AL., EUR. RESPIR. J., (2010), vol. 36, pages 792 - 799
    - DUMITRASCU ET AL., CIRCULATION, (2006), vol. 113, pages 286 - 295
    - 0. EVGENOV ET AL., AM. J. RESPIR. CRIT. CARE MED., (2007), vol. 176, pages 1138 - 1145
    - N. WEISSMANN ET AL., AM. J. PHYSIOL. LUNG CELL. MOL. PHYSIOL., (2009), vol. 297, pages L658 - 665
    - P. KALK ET AL., BRIT. J. PHARMACOL., (2006), vol. 148, pages 853 - 859
    - BENZ ET AL., KIDNEY BLOOD PRESS. RES., (2007), vol. 30, pages 224 - 233
    - Y. WANG ET AL., KIDNEY INTL., (2005), vol. 68, pages 47 - 61
    - I.M. OTT ET AL., PLOS ONE, (2012), vol. 7, page E42623
    - J.-P. STASCH ET AL., BRIT. J. PHARMACOL., (2002), vol. 136, pages 773 - 783
    - A. SCHAFER ET AL., ARTERIOSCLER. THROMB. VASC. BIOL., (2006), vol. 26, pages 2813 - 2818
    - C. STIEF ET AL., EUR. UROL., (2008), vol. 53, pages 1236 - 1244
    - B. FIBBI; 2010 ET AL., J. SEX. MED., vol. 7, pages 59 - 69
    - D.Z ELLIS, CELL. PHYSIOL. BIOCHEM., (2011), vol. 28, pages 1145 - 1154
    - L.S. HOFFMANN ET AL., NATURE COMMUNICATIONS, (2015), vol. 6
    - J. JOSHUA ET AL., ENDOCRINOLOGY, (2014), vol. 155, pages 4720 - 4730
    - BIRGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.